These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 6207511)

  • 1. Implications of neuropeptides in neurological diseases.
    Sagar SM; Beal MF; Marshall PE; Landis DM; Martin JB
    Peptides; 1984; 5 Suppl 1():255-62. PubMed ID: 6207511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Putative peptide neurotransmitters in human neuropathology: a review of topography and clinical implications.
    Constantinidis J; Bouras C; Richard J
    Clin Neuropathol; 1983; 2(2):47-54. PubMed ID: 6189657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuropeptides in neurological disease.
    Beal MF; Martin JB
    Ann Neurol; 1986 Nov; 20(5):547-65. PubMed ID: 2947536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postmortem studies of peptides in Alzheimer's disease and Huntington's disease.
    Rossor M; Emson P; Dawbarn D; Dockray G; Mountjoy C; Roth M
    Res Publ Assoc Res Nerv Ment Dis; 1986; 64():259-77. PubMed ID: 2425405
    [No Abstract]   [Full Text] [Related]  

  • 5. Localization of hypophysiotropic peptides and other biologically active peptides within the brain.
    Elde R; Hökfelt T
    Annu Rev Physiol; 1979; 41():587-602. PubMed ID: 107852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biotransformation of neuropeptides.
    Griffths EC; McDermott JR
    Neuroendocrinology; 1984 Dec; 39(6):573-81. PubMed ID: 6083500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Involvement of non-opioid peptides in the pathogenesis of neurological and psychiatric disorders: evidence from CSF and post-mortem studies.
    Nemeroff CB; Bissette G
    Prog Clin Biol Res; 1985; 192():333-41. PubMed ID: 2934745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic exposure to hypergravity affects thyrotropin-releasing hormone levels in rat brainstem and cerebellum.
    Daunton NG; Tang F; Corcoran ML; Fox RA; Man SY
    Biol Signals Recept; 1998; 7(6):337-44. PubMed ID: 9873155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatostatin alterations and brain diseases.
    Epelbaum J; Agid Y; Enjalbert A; Hamon M; Javoy-Agid F; Kordon C; Lamour Y; Moyse E
    Adv Exp Med Biol; 1985; 188():261-74. PubMed ID: 2863935
    [No Abstract]   [Full Text] [Related]  

  • 10. Biosynthesis, packaging, transport, and release of brain peptides.
    McKelvy JF; Epelbaum J
    Res Publ Assoc Res Nerv Ment Dis; 1978; 56():195-215. PubMed ID: 74843
    [No Abstract]   [Full Text] [Related]  

  • 11. Regional distribution of methionine-enkephalin and substance P-like immunoreactivity in normal human brain and in Huntington's disease.
    Emson PC; Arregui A; Clement-Jones V; Sandberg BE; Rossor M
    Brain Res; 1980 Oct; 199(1):147-60. PubMed ID: 6157454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Neuropeptides in Alzheimer's disease].
    Jiménez-Corral C; Morán-Sánchez JC; Alonso-Navarro H
    Rev Neurol; 2006 Mar 16-31; 42(6):354-9. PubMed ID: 16575772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuropeptides: anticonvulsant and convulsant mechanisms in epileptic model systems and in humans.
    Bajorek JG; Lee RJ; Lomax P
    Adv Neurol; 1986; 44():489-500. PubMed ID: 2871723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regional brain concentrations of neuropeptides in Huntington's chorea and schizophrenia.
    Nemeroff CB; Youngblood WW; Manberg PJ; Prange AJ; Kizer JS
    Science; 1983 Sep; 221(4614):972-5. PubMed ID: 6136092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of ketamine on the cholecystokinin, somatostatin, substance P, and thyrotropin releasing hormone in discrete regions of rat brain.
    Pongdhana K; Ogawa N; Hirose Y; Ono T; Kosaka F; Mori A
    Neurochem Res; 1987 Jan; 12(1):73-7. PubMed ID: 2437471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunocytochemical studies of substance P and Met-enkephalin in the basal ganglia and substantia nigra in Huntington's, Parkinson's and Alzheimer's diseases.
    Grafe MR; Forno LS; Eng LF
    J Neuropathol Exp Neurol; 1985 Jan; 44(1):47-59. PubMed ID: 2578185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distribution of neuropeptides in the limbic system of the rat: the hippocampus.
    Roberts GW; Woodhams PL; Polak JM; Crow TJ
    Neuroscience; 1984 Jan; 11(1):35-77. PubMed ID: 6200800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Somatostatin: alterations in the central nervous system in neurological diseases.
    Beal MF; Uhl G; Mazurek MF; Kowall N; Martin JB
    Res Publ Assoc Res Nerv Ment Dis; 1986; 64():215-57. PubMed ID: 2873636
    [No Abstract]   [Full Text] [Related]  

  • 19. [Neuropeptides and mental disorders].
    Shibuya H
    Nihon Rinsho; 1983 May; 41(5):1001-8. PubMed ID: 6195368
    [No Abstract]   [Full Text] [Related]  

  • 20. Neuropeptides in Alzheimer's disease: a postmortem study.
    Nemeroff CB; Kizer JS; Reynolds GP; Bissette G
    Regul Pept; 1989 Apr; 25(1):123-30. PubMed ID: 2566190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.